Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosis
Show others and affiliations
2019 (English)In: Annals of clinical and translational neurology, E-ISSN 2328-9503Article in journal (Refereed) Epub ahead of print
Abstract [en]

Objective Mutations in Fused in Sarcoma (FUS or TLS) are the fourth most prevalent in Western European familial amyotrophic lateral sclerosis (ALS) populations and have been associated with causing both early and very late disease onset. FUS aggregation, DNA repair deficiency, and genomic instability are contributors to the pathophysiology of FUS-ALS, but their clinical significance per se and their influence on the clinical variability have yet to be sufficiently investigated. The aim of this study was to analyze genotype-phenotype correlations and malignancy rates in a newly compiled FUS-ALS cohort. Methods We cross-sectionally reviewed FUS-ALS patient histories in a multicenter cohort with 36 novel cases and did a meta-analysis of published FUS-ALS cases reporting the largest genotype-phenotype correlation of FUS-ALS. Results The age of onset (median 39 years, range 11-80) was positively correlated with the disease duration. C-terminal domain mutations were found in 90%. Among all, P525L and truncating/ frameshift mutations most frequently caused juvenile onset, rapid disease progression, and atypical ALS often associated with negative family history while the R521 mutation site was associated with late disease onset and pure spinal phenotype. Malignancies were found in one of 40 patients. Interpretation We report the largest genotype-phenotype correlation of FUS-ALS, which enables a careful prediction of the clinical course in newly diagnosed patients. In this cohort, FUS-ALS patients did not have an increased risk for malignant diseases.

Place, publisher, year, edition, pages
Wiley Periodicals , 2019.
National Category
Neurosciences Neurology
Identifiers
URN: urn:nbn:se:umu:diva-165488DOI: 10.1002/acn3.50930ISI: 000493814800001PubMedID: 31682085OAI: oai:DiVA.org:umu-165488DiVA, id: diva2:1376930
Available from: 2019-12-10 Created: 2019-12-10 Last updated: 2019-12-10

Open Access in DiVA

fulltext(658 kB)16 downloads
File information
File name FULLTEXT01.pdfFile size 658 kBChecksum SHA-512
da7e455a463a411b02a5d62edd33dfcca8d6766eaedb8a10f79aaa35940485248b25e9bf28fd11f732cabbf251b24234e3f2ab190ed3e5fbbdaf898f49dddaa3
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Andersen, Peter M.
By organisation
Department of Pharmacology and Clinical Neuroscience
In the same journal
Annals of clinical and translational neurology
NeurosciencesNeurology

Search outside of DiVA

GoogleGoogle Scholar
Total: 16 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 17 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf